Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

NCT01299727 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped Completion of follow-up period

Conditions

Sanfilippo Syndrome

Interventions

BIOLOGICAL: rhHNS-10 mg
BIOLOGICAL: rhHNS-45 mg
BIOLOGICAL: rhHNS-90 mg

Sponsor

Shire